全球自体免疫多腺体综合征 1 型市场（按诊断、治疗、剂型、给药途径、发病年龄、分销渠道和地区划分）

2025 年全球 1 型自体免疫多腺体症候群市场规模估计为 2.891 亿美元，预计到 2032 年将达到 3.628 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 3.3%。

数字。 2025年1型自体免疫多腺体症候群全球市场占有率（%）（按地区）

自体免疫多内分泌腺症候群 1 型 (APS1)，也称为自体免疫多内分泌腺病-腺泡病-外胚层营养不良症 (APECED)，是一种罕见的多系统疾病，由肾上腺、副甲状腺、性腺和其他组织等多个内分泌腺的自体免疫破坏引起。 APS1 是由 AIRE 基因（自体免疫调节剂）突变引起的，该基因控制组织特异性基因的表达并促进中枢耐受诱导。 AIRE功能丧失导致免疫耐受性失败，引发多器官自体免疫攻击。 APS1 的常见临床特征包括甲状旁腺功能低下症、原发性肾上腺功能不全、慢性黏膜皮肤念珠菌症和性腺功能障碍。由于 APS1 发病早且严重涉及多重器官，因此需要对患者进行终身管理和监测。

市场动态：

由于 APS1 在世界各地的盛行率不断上升，全球自体免疫多腺体症候群 1 型市场预计将呈现丰厚的成长机会。针对高风险族群的基因筛检计画正在提高早期诊断率。加强阐明免疫疾病机制和开发新型耐受诱导疗法的研究也在推动市场成长。然而，缺乏核准的标靶药物和有限的治疗选择继续阻碍市场的发展。同时，提高人们对罕见疾病的认识并专注于开发新的生技药品的努力可能会创造有吸引力的机会。作为一种罕见疾病，APS-1 可能受益于孤儿药资格和其他鼓励研发的诱因。正在进行的研究旨在提高我们对潜在机制的理解，并实现更有针对性和更有效的治疗。然而，有限的患者数量对大规模临床试验和药物开发构成了挑战。

製药公司、研究机构和患者权益团体之间的合作对于推进 APS-1 研究和改善患有这种复杂的自体免疫综合症的人的生活品质至关重要。市场动态受到医学进步和支持罕见疾病治疗的监管环境的影响。

本研究的主要特点

本报告对全球自体免疫多腺体综合征 1 型市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。

它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。

它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。

全球自体免疫多腺体综合征 1 型市场中的关键公司是根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行介绍的。

研究涉及的主要企业包括辉瑞、GlaxoSmithKline Plc史克、诺华、迈兰、梯瓦、赛诺菲、罗氏、Zydus 卡迪拉、鲁宾、Amneal Pharmaceuticals LLC、西普拉、奥罗拉（Aurora）、Cipla Inc.、Cipla Inc.、Amneal Pharmacesticals LLC、Ciputicals LLC、Flenutical Limited、礼来公司、太阳製药工业有限公司、艾尔建、百时美施贵宝公司、工业、雅培和 LEO Pharma A/S。

本报告的见解将帮助负责人和企业经营团队未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。

本研究报告针对该产业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和财务分析师。

相关人员可以透过用于分析全球自体免疫多腺体综合征 1 型市场的各种策略矩阵来促进决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
• 影响分析
• 主要亮点
• 监管情景
• 服务产品组合
• PEST分析
• 波特分析
• 併购场景
• 管道分析

4. 全球自体免疫多腺体症候群 1 型市场-冠状病毒 (COVID-19) 大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 全球自体免疫多腺体症候群 1 型市场（依诊断），2020 年至 2032 年

• 血清自体免疫筛检
• 终末器官功能测试
• 血液检查

6. 全球自体免疫多腺体症候群 1 型市场（依治疗方法划分），2020 年至 2032 年

• 药品
• 抗真菌剂
• Fluconazole
• Itraconazole
• 骨化三醇
• 皮质类固醇
• 其他（荷尔蒙补充疗法等）

7. 2020 年至 2032 年全球 1 型自体免疫免疫多腺体症候群市场（依剂型划分）

• 锭剂
• 胶囊
• 其他的

8. 全球自体免疫多腺体症候群 1 型市场（依给药途径），2020 年至 2032 年

• 口服
• 其他的

9. 2020 年至 2032 年全球 1 型自体免疫免疫多腺体症候群市场（依发病年龄）

• 孩子们
• 成人
• 青春期

第 10 章。 2020 年至 2032 年按分销管道分類的 1 型自体免疫免疫性多腺体综合征市场

• 医院药房
• 零售药局
• 网路药局

第 11 章。 2020 年至 2032 年按地区分類的 1 型自体免疫免疫性多腺体综合征市场

• 北美洲
• 欧洲

Global Autoimmune Polyglandular Syndrome Type 1 Market is estimated to be valued at USD 289.1 Mn in 2025 and is expected to reach USD 362.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.

Figure. Global Autoimmune Polyglandular Syndrome Type 1 Market Share (%), By Region 2025

Autoimmune polyglandular syndrome type 1 (APS1), also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare multisystem disorder caused by the autoimmune destruction of several endocrine glands like the adrenals, parathyroid glands, gonads, and other tissues. APS1 results from mutations in the AIRE gene (autoimmune regulator), which regulates the expression of tissue-specific genes and promotes central tolerance induction. Loss of function of AIRE leads to failures in immune tolerance, leading to autoimmune attacks on multiple organs. Common clinical features of APS1 include hypoparathyroidism, primary adrenal insufficiency, chronic mucocutaneous candidiasis, and gonadal failure. Early onset and severity of multiorgan involvement require lifelong management and monitoring of APS1 patients.

Market Dynamics:

The global autoimmune polyglandular syndrome type 1 market is projected to witness lucrative growth opportunities owing to rising APS1 disease prevalence worldwide. Genetic screening programs for high-risk ethnic populations are driving the early diagnosis rate. Increasing research into understanding immunological disease mechanisms and developing novel tolerance-inducing therapies is also fueling market growth. However, a lack of approved targeted drugs and limited treatment options continue to hamper the market. Meanwhile, initiatives to enhance rare disease awareness and focus on developing new biologics hold potential to create attractive opportunities. As a rare disease, APS-1 may benefit from orphan drug designations and incentives to encourage research and development. Ongoing research aims to deepen our understanding of the underlying mechanisms, allowing for more targeted and effective treatments. However, the limited patient population poses challenges for large-scale clinical trials and drug development.

Collaboration between pharmaceutical companies, research institutions, and patient advocacy groups is crucial for advancing APS-1 research and improving the quality of life for individuals affected by this complex autoimmune syndrome. The market dynamics are influenced by both medical advancements and the regulatory landscape supporting rare disease treatments.

Key features of the study:

This report provides in-depth analysis of the global autoimmune polyglandular syndrome type 1 market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global autoimmune polyglandular syndrome type 1 market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., Zydus Cadila, Lupin, Amneal Pharmaceuticals LLC., Cipla Inc., Aurobindo Pharma, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Allergan, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Abbott, and LEO Pharma A/S.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global autoimmune polyglandular syndrome type 1 market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global autoimmune polyglandular syndrome type 1 market

Detailed Segmentation:

• By Diagnosis
  • Serum Autoimmune Screen
  • End-organ Function Tests
  • Blood Tests
• By Treatment
  • Medication
  • Antifungal Agents
  • Fluconazole
  • Itraconazole
  • Calcitriol
  • Corticosteroids
  • Others (Hormone Replacement Therapy, etc.)
• By Dosage Form
  • Tablet
  • Capsule
  • Others
• By Route of Administration
  • Oral
  • Others
• By Age of Onset
  • Childhood
  • Adult
  • Adolescent
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Key Players:
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F.Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Amneal Pharmaceuticals LLC.
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Eli Lilly and Company
  • Sun Pharmaceutical Industries Ltd.
  • Allergan
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Abbott
  • LEO Pharma A/S

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel
  • Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increased incidence of autoimmune disorders
  • Growing Genetic Research Insights
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Service offering Portfolio
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Pipeline Analysis

4. Global Autoimmune Polyglandular Syndrome Type 1 Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Diagnosis, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Serum Autoimmune Screen
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• End-organ Function Tests
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Blood Tests
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Treatment, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Medication
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Antifungal Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Fluconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Itraconazole
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Calcitriol
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others (Hormone Replacement Therapy, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Dosage Form, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tablet
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Capsule
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Route of Administration, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Age of Onset, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Childhood
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Adolescent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

10. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

11. Global Autoimmune Polyglandular Syndrome Type 1 Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021 -2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Diagnosis, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Age of Onset, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • North Africa
  • Central Africa
  • South Africa

12. Competitive Landscape

• Pfizer Inc.
  • Company Highlights
  • Product & Service Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Hoffmann-La Roche Ltd.
• Zydus Cadila
• Lupin
• Amneal Pharmaceuticals LLC.
• Cipla Inc.
• Aurobindo Pharma
• Glenmark Pharmaceuticals Limited
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Allergan
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Abbott
• LEO Pharma A/S
• Analyst Views

13. Section

• Research Methodology
• About us